

Recent Advances in Management of Gastrointestinal Stromal Tumours

Essay

Submitted for partial fulfillment of master degree in
General Surgery

By

Hany hassaneen hassaneen salem

M.B., B.ch

Supervised by

Prof. Dr. Moemen Abou Shloa

*Professor of General Surgery, Head of General Surgery
Department*

Faculty of medicine – Ain Shams University

Dr. Wafi Fouad Salib

*Assistant Professor of General Surgery
Faculty of medicine – Ain Shams University*

Dr. Haitham Mostafa ElMaleh

*Lecture of General Surgery
Faculty of medicine – Ain Shams University*

Faculty of Medicine

Ain Shams University

2012

List of Contents

Title	Page
○ List of Figures	i
○ List of Tables.....	iii
○ List of Abbreviations	iv
● Introduction	1
● Clinical picture	6
1-Predisposing factors	6
2-Pathophysiology	7
A)Epidemiology	7
B)Cells of Origin (Interstitial cells of Cajal)	9
C)Pathological features	10
1-Gross pathology	10
2-Histopathological features	14
3-Clinical presentation	30
● Diagnosis of Gastrointestinal stromal tumors	33
A) Investigations for GISTs	33
1) Blood tests.....	33
2) Plain radiography	33
3) Barium x-ray	35
4) Ultrasonography	39
5) Endoscopic ultrasound (EUS)	40
6) Angiography.....	44
7) Computed Tomography (CT) of the Abdomen...	46
8) Magnetic Resonance Imaging (MRI)	53
9) Positron emission tomography (PET)	57
10)Biopsy	60
11)Immunohistochemisticmarkers	61

List of Contents

Title	Page
• Treatment of Gastrointestinal stromal tumors	65
Multidisciplinary management	65
Treatment options	67
1)Surgical treatment	67
-Surgery for Primary Resectable GISTs	69
-Laparoscopic approach	85
-Surgery for Metastatic, Advanced, & Drug-Resistant GISTs	87
2) Chemotherapy	90
1-Imatinib	91
2-Sunitinib	98
3-Novel Agents (Investigational Agents)	102
Treatment strategy	107
1-Management of localized GIST	107
2-Management of Locally advanced, metastatic, and recurrent GIST.....	111
3)Options for liver metastasis	116
1-Surgical resection	116
2-Radiofrequency ablation (RFA)	117
3-Hepatic artery chemoembolization (HACE)	118
4-Liver transplantation	119
4)Survival and Follow up	120
○ Summary	127
○ References	131
○ Arabic summary	--

List of Figures

No.	Figure	Page
1	Interstitial cells of Cajal	10
2	Endoscopic image of GIST in fundus of stomach, seen on retroflexion	11
3	Same GIST seen on forward view of the endoscope showing overlying clot	11
4	Histologic spectrum of gastric gastrointestinal stromal tumour	18
5	Histologic spectrum of intestinal GISTs.	20
6	Histologic spectrum of small intestinal GIST	21
7	Schematic representation of KIT and platelet-derived growth factor receptor alpha (PDGFRA) molecules and KIT and PDGFRA mutations..	24
8	Schematic representation of molecular pathogenesis of GIST	25
9	Gastric GIST arises from the lesser curvature	34
10	Gastric GIST arises from greater curve.	34
11	Gastrointestinal stromal tumor with central bull's eye appearance, which is compatible with contrast material collection in ulceration.	36
12	A Barium meal showing a smooth filling defect at the greater curvature.	37
13	Gastric GIST over the lesser curve. Barium meal shows a typical submucosal lesion with overlying mucosal ulceration.	37
14	Enteroclysis showing Distal jejunal GIST	38
15	A large exophytic gastric GIST arises from the greater curve. Transverse view of trans-abdominal sono-graphy	40
16	Ultrasound showing Benign GIST of gastric body	40
17	Small gastric GIST shown by EUS.	43
18	Left parasagittal view of Transrectal sonography shows an exophytic hypoechoic mass arising from the anterolateral wall of rectum	43
19	Selective superior mesenteric angiography for a Patient with an obscure GI hemorrhage showing tumor blush, indicating a small intestinal tumor.	44

List of Figures (Cont.)

No.	Figure	Page
20	Ileal GIST presented with intermittent gastrointestinal bleeding by Superior mesenteric angiography	45
21	CT show large ileal GIST with central necrosis, cavitation and sinus tract formation	47
22	: Contrast-enhanced axial CT show Gastric GIST arises from greater curve.	48
23	Jejunal GIST by CT	49
24	Gastric GIST by CT	49
25	Benign GIST from the lateral aspect of the gastric body.	50
26	GIST of the stomach with liver metastases	50
27	GIST of the gastric antrum and body with extraluminal and intraluminal tumor extension	51
28	GIST of gastric fundus with homogenous intra-luminal GIST along the lesser curve, extending into the gastrohepatic ligament	52
29	. large GIST of the small bowel mesentery	52
30	GIST of the lesser curve stomach by CT, MRI, & Ultrasonography	55
31	Rectal GIST by MRI	56
32	PET can detect imatinib response earlier than CT.	59
33	. 1 Normal esophagus, 2 and 3 esophagectomy	71
34	Sagittal and transverse CT scans of a gastrointestinal stromal tumour of the gastric cardia (incidentally detected)	75
35	CT scan of a 10 × 12-cm GIST of the stomach	76
36	Gastrointestinal stromal tumour of the second part of the duodenum before and after imatinib therapy	78
37	Pre-surgery anatomy and pancreaduodenectomy either sparing the pylorus or with resection of the pylorus	79
38	CT scan of a highly malignant GIST of the proximal jejunum, closely related to but not infiltrating the mesentery of the transverse colon	81
39	CT scan of a gastrointestinal stromal tumour of the ascending colon	82
40	CT scan of a GIST of the lower rectum with presacral	85

	extension	
41	Laparoscopic resection of 2 cm gastric GIST	87
42	Hepatic artery embolization of GIST	119

List of Tables

No.	Table	Page
1	RECIST and modified CT response evaluation criteria	126

List of Abbreviations

ALK	Anaplastic Lymphoma Kinase
BID	Twice daily
CB	Clinical benefit
CML	Chronic myeloid leukemia
CR	Complete response
CT	Computed Tomography
DFS	Disease free survival
DOG1	Discovered on GIST
EGIST	Extra gastrointestinal stromal tumours
ESMO	European Society for Medical Oncology
EUS	Endoscopic ultrasonography
FNA	Fine needle aspiration
FDA	Food and drug administration
FDG	Fluoro-2-deoxy-D-glucose
GI	Gastrointestinal
GISTs	Gastrointestinal stromal tumors
HAE	Hepatic artery embolization
HACE	Hepatic arterial chemoembolization
HPF	High power field

ICCs	Interstitial cells of Cajal
IHC	Immunohistochemical
LMP	Low malignant potential
MRI	Magnetic Resonance Imaging
mTOR	mammalian target of rapamycin
NCCN	National Comprehensive Cancer Network
OD	Once daily
OS	Overall survival
PAS	periodic acid Schiff
PD	Progressive disease
PDGFRα	Platelet-derived growth factor receptor alpha
PET	Positron Emission Tomography
PFS	Progression-free survival
PR	Partial response
RFA	Radiofrequency Ablation
RFS	Recurrence-free survival
SCF	Stem cell factor
SD	Stable disease
SMA	Smooth muscle actin
SMTs	Submucosal tumours
TKI	tyrosine kinase inhibitor
TTP	time to disease progression
UGI	Upper gastrointestinal
VEGFR	Vascular endothelial growth factor receptor

Introduction

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Neoplastic GIST cells seem to arise from a common precursor cell, which gives rise to the interstitial cells of Cajal in the normal myenteric plexus. **(Demetri et al., 2010).**

The incidence of GISTs is estimated to be approximately 10-20 per million people, per year. Malignancy possibility is 20-30%. However, the precise incidence of GISTs is unknown because of the incomplete definition and classification. Over 90% of GISTs occur in adults over 40 years old, with a median age of 63 years. However, GIST cases have been reported in all ages, including children. The incidence between the sexes is the same, although a study reported that there is a slight predominance of males. There are no elements that indicate any association with geographic location, ethnicity, race or occupation. **(Tran et al., 2005).**

The most common site of primary tumors is the stomach (39% to 70%); followed by the small intestine (31% to 45%); colon, rectum, and anus (10% to 16%); and mesentery and peritoneum (8%); with rare cases arising in the esophagus. **(Miettinen et al., 2000).** Metastatic disease is most often found in the liver, peritoneum, and omentum. **(Lasota, 2001).** Less

Introduction

common metastatic sites include lung and bone. **(Hughes et al., 2004).**

GISTs most commonly results from activating mutations in one of the receptor protein tyrosine kinases: KIT (CD117) or platelet-derived growth factor receptor alpha (PDGFRA). **(Demetri et al., 2010).**

GISTs have specific immunohistochemical (IHC) markers: 95% are CD-117 positive, 70-80% are CD34 positive, and 20-30% are smooth muscle actin (SMA) positive, whereas desmin is positive in less than 5% of GISTs. Discovered on GIST (DOG) 1, known also as ANO1, has emerged in recent years as a promising biomarker for GISTs, since recent studies documented that DOG1 antibodies are more sensitive than kit antibodies in detecting gastric GISTs and tumours carrying PDGFR alpha mutations. **(Caterino et al., 2011).**

GISTs have an uncertain clinical behavior ranging from benign to frankly malignant, making the outcome totally unpredictable. Multiple parameters have been considered as predictors of malignancy. Size and mitotic count appear to be the most useful predictors of the malignant behaviour. **(Gupta et al., 2008).**

Introduction

The clinical presentation of patients with GISTs varies depending on the anatomic location of the tumor and the tumor size and aggressiveness. **(Demetri, 2008)**. Approximately 70% of GISTs are symptomatic, 20% are asymptomatic and identified during staging or follow-up for other malignancies, while 10% are discovered during autopsy. **(Gold & DeMatteo, 2006)**.

GISTs vary greatly in size from a few millimeters to >30 cm, the median size though is between 5 cm and 8 cm. Macroscopically, GIST usually has an exophytic growth and as a result, the intra-operative appearance commonly resembles of a mass, that is attached to the stomach, projecting into the abdominal cavity and displacing all the other organs. **(Stamatakis et al, 2009)**. Small GISTs may form solid subserosal, intramural, or, less frequently, polypoid intraluminal masses. Large tumors tend to form external masses attached to the outer aspect of the gut involving the muscular layers. GISTs morphology is quite varied; the tumors are composed of the following: Spindle cells (70%), Epithelioid cells (20%), Mixed spindle and epithelioid cells (10%). **(Corless & Heinrich, 2008)**.

GISTs encompass a broad continuum of histologic patterns, ranging from bland-appearing tumors with very low mitotic activity (often previously designated leiomyomas) to very

Introduction

aggressive-appearing patterns (previously often called leiomyosarcomas). **(Edge et al., 2010).**

Treatment may involve surgery and/or the use of tyrosine kinase inhibitors (TKI) depending on the extent of disease and tumor sensitivity to TKIs. **(Judson & Demetri, 2007).**

The standard of care in the management of patients with GISTs had rapidly changed after the introduction of TKIs, such as imatinib mesylate and sunitinib malate. **(Demetri et al., 2010).** Most GISTs have mutations in the KIT or PDGFRA gene, causing activation of tyrosine kinase. Imatinib (a TKI) is the first-line palliative treatment for advanced GISTs. Sunitinib was introduced for patients with mutations not responsive to imatinib. **(Sjölund et al., 2010).**

Despite the proven success of imatinib and other newer tyrosine-kinase inhibitors, surgical resection remains the treatment of choice and offers the only chance for cure from GIST. The aim of surgical treatment is complete resection, avoiding tumour rupture, preferring wedge resections whenever possible; lymphadenectomy is not recommended due to the rarity of nodal metastasis, with the exception of GISTs occurring in a setting of Carney triad, that usually show an higher rate of lymph nodes metastasis. **(Zhang et al., 2010).**

Introduction

The main operative principle is resection of the tumor with negative microscopic margins. Wide resection of the tumor (e.g., 2 cm margin) has not been shown to improve outcomes and expert consensus is that such dogmatic adherence to a particular width of margin is not necessary or recommended. (**Bucher et al., 2006**).

Because adequate resection for small malignant GISTs can be achieved by wedge resection, minimally invasive surgery techniques can be considered in selected cases. In recent years, numerous published reports of laparoscopic resection of gastric GISTs have demonstrated the feasibility and safety of this technique. (**Bedard et al., 2006**).

Clinical picture

1-Predisposing factors:

In rare cases, GISTs have been found in several members within the same family. These family members inherited a gene mutation that leads to GIST. But most GISTs are sporadic and their cause is unknown (**Corless et al., 2004**).

Familial gastrointestinal stromal tumor syndrome is a rare, inherited condition leading to increased risk of developing one or more GISTs. The mutated gene passed from one generation to the next in the familial GISTs syndrome is usually the c-kit gene. This is the same gene that is mutated in sporadic GISTs. But patients with the familial form have a mutation in all the cells of their body, whereas only the GIST cells are affected by this mutation in the sporadic form. Very rarely, another gene, the Platelet derived growth factor alpha (PDGFRA) gene (instead of the c-kit gene) is responsible for GISTs in some families. Patients with this inherited condition tend to develop GISTs at a younger age than do sporadic GIST patients and are more likely to have multiple GISTs. They may also have skin spots similar to those in neurofibromatosis. Until recently, when tests for c-kit gene and PDGFRA gene became available, some of these patients

Clinical picture

were mistakenly thought to have neurofibromatosis (**Raut et al., 2007**).

Carney triad, familial gastrointestinal stromal tumor syndrome, and von Recklinghausen syndrome are associated with an elevated risk of developing GISTs. Specific associations of GISTs with other malignancies have not been determined, but GISTs are not infrequently seen with other neoplasms. No risk factors or causative factors have been identified (**Dirnhofera & Leyvrazb, 2009**).

GISTs have rarely been reported in patients with AIDS. The few sporadic cases are from pediatric and adult patients with AIDS who were diagnosed with malignant GISTs (**Padula et al., 2005**).

2-Pathophysiology:

A-Epidemiology:

Although gastrointestinal stromal tumors are generally regarded as a rare tumor, it is the most common (80%) mesenchymal neoplasm of the GI tract and represents about 5% of all sarcomas (**Bayraktar et al., 2010**).

The incidence of GISTs is estimated to be approximately 10-20 per million people, per year. Malignancy possibility is 20-

Clinical picture

30%. However, the precise incidence of GIST is unknown because of the incomplete definition and classification.

Over 90% of GISTs occur in adults over 40 years old, in a median age of 63 years. However, GISTs cases have been reported in all ages, including children. The incidence between the sexes is the same, although a study reported that there is a slight predominance of males. There are no elements that indicate any association with geographic location, ethnicity, race or occupation.

GISTs tumors may occur anywhere along the length of the digestive tract from the esophagus to the anus. They account for 1–3% of gastric neoplasms, 20% of small bowel tumors and 0.2–1% of colorectal tumors (**Nikolaos et al., 2005**).

The most common location of GIST is stomach (50-60%) and small intestine (30%-40%). Five to ten percent of GISTs arise from the colon and rectum, and 5% are located in the esophagus. Other less common locations are those outside of the GI tract, like mesentery, retroperitoneum and omentum. However, there have been reported rare cases in the gallbladder, pancreas, liver and urinary bladder. In cases, where GIST occurs outside the GI tract, the tumors are known as extra - gastrointestinal stromal tumors (EGISTs) (**Stamatakis et al., 2009**).